VALNEVA

A European company (*Societas Europaea* or SE) with a Management and a Supervisory Board
With a share capital of €11,383,243.14
Registered office: World Trade Center Lyon, Tour Oxygène,
10-12 Boulevard Marius Vivier Merle, 69003 Lyon
R.C.S Lyon 422 497 560

MS. LISA SHAW-MAROTTO

PROPOSAL OF APPOINTMENT AS SUPERVISORY BOARD MEMBER OF VALNEVA SE
RESOLUTION No. 14 OF THE COMBINED GENERAL MEETING OF JUNE 30, 2016
ARTICLE R. 225-83, 5° OF THE FRENCH COMMERCIAL CODE

Ms. Louisa Mary Shaw, commonly known as Lisa Shaw-Marotto, an American national, aged 49, is a seasoned executive with more than two decades of commercial experience in the pharmaceutical industry. Currently, Ms. Shaw-Marotto is the President of Executive Perspective Consulting LLC, a Life Sciences Consulting company she founded in 2014. Prior to this, Ms. Shaw-Marotto had a long and successful career at Merck & Co. where she held various commercial roles culminating in her role as Vice President of Marketing leading Merck's Global Commercial Services organization including market research, training, marketing communications (advertising, promotion and education) and marketing operations (2011-2013). Ms. Shaw-Marotto has also accumulated a wealth of experience in several therapeutic areas in Merck's vaccines and pharmaceuticals divisions, as well as in a corporate staff role. Ms. Shaw-Marotto was recognized as Merck's "Rising Star" for the 2010 HealthCare Business Women's Association. Prior to joining Merck in 1989, Ms. Shaw-Marotto was a research assistant at an immunology biotechnology company in Sydney, Australia and holds a Biomedical Science Degree from the University of Technology in Sydney, Australia. From 2014, Ms. Shaw-Marotto has been a Director for the non-profit organization “Live the List”.

Currently, Ms. Shaw-Marotto does not hold any shares of the company Valneva SE.

VALNEVA

A European company (*Societas Europaea* or SE) with a Management and a Supervisory Board
With a share capital of €11,383,243.14
Registered office: World Trade Center Lyon, Tour Oxygène,
10-12 Boulevard Marius Vivier Merle, 69003 Lyon
R.C.S Lyon 422 497 560

MR. RALF CLEMENS

PROPOSAL OF APPOINTMENT AS SUPERVISORY BOARD MEMBER OF VALNEVA SE
RESOLUTION No. 15 OF THE COMBINED GENERAL MEETING OF JUNE 30, 2016
ARTICLE R. 225-83, 5° OF THE FRENCH COMMERCIAL CODE

Mr. Ralf Leo Clemens, a German national, aged 64, is a medical Doctor and obtained his Ph.D. at the Johannes-Gutenberg University in Mainz, Germany. Mr. Clemens also holds an executive business degree from the Wharton Business School, Philadelphia, USA. Currently, Mr. Clemens is Principal and Founder of GRID EUROPE Consulting, a consulting firm specialized in the field of infectious diseases. Mr. Clemens has been working in the vaccine industry since 1988 and has held various senior scientific and business positions such as VP Global Vaccines Development (1991-2000) and VP Vaccines and Pharmaceutical Business (2001-2006) at GSK. Thereafter, he served as VP and Head Global Vaccine Development at Novartis Vaccines & Diagnostics (2006-2011), and as SVP and Head for Takeda's global vaccine division (2012-2015). Mr. Clemens has also been a Senior Advisor to the Bill & Melinda Gates Foundation since 2012. Mr. Clemens has been a member of the CureVac Supervisory Board since March 2016. He also serves on the Scientific Advisory Boards of AREF (African Research Excellence Fund) and AERAS.

Currently, Mr. Ralf Clemens does not hold any shares of the Company Valneva SE.